Paul Wannamaker

High Sensitivity of Human Leukocyte Antigen–B*5701 as a Marker for Immunologically Confirmed Abacavir Hypersensitivity in White and Black Patients

Michael S. Saag, Rukmini Balu, Elizabeth J. Phillips et al. · Clinical Infectious Diseases · 2008 · 431 citations · Full text

Life Sciences, Dermatology, Immunology +12

The KLEAN study of fosamprenavir-ritonavir versus lopinavir-ritonavir, each in combination with abacavir-lamivudine, for initial treatment of HIV infection over 48 weeks: a randomised non-inferiority trial

Joseph J. Eron, Patrick Yéni, Joseph Gathe et al. · The Lancet · 2006 · 342 citations

Pharmacy, Infectious Diseases, Pharmacotherapy +13

Randomized, double-blind, placebo-matched, multicenter trial of abacavir/lamivudine or tenofovir/emtricitabine with lopinavir/ritonavir for initial HIV treatment

Kimberly Y. Smith, Parul Patel, Derek M. Fine et al. · AIDS · 2009 · 217 citations

Pharmacy, Pharmacology, Pharmacotherapy +17

The NEAT Study: A 48-Week Open-Label Study to Compare the Antiviral Efficacy and Safety of GW433908 Versus Nelfinavir in Antiretroviral Therapy???Naive HIV-1-Infected Patients

A Rodriguez‐French, Jack Boghossian, Glenda Gray et al. · JAIDS Journal of Acquired Immune Deficiency Syndromes · 2003 · 150 citations

Medicine, Pharmacology, Pharmacotherapy +17

First large, multicenter, open-label study utilizing HLA-B*5701 screening for abacavir hypersensitivity in North America

Benjamin Young, Kathleen Squires, Parul Patel et al. · AIDS · 2008 · 98 citations

Life Sciences, Immunology, Pharmacotherapy +14